Stock Events

Supernus Pharmaceuticals 

€27.6
13
+€0+0% Friday 06:03

Statistics

Day High
27.6
Day Low
27.6
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
1.94B
P/E Ratio
390.67
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.27
0.05
0.37
0.7
Expected EPS
0.41263516786000004
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow S49.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap21.38B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly with Supernus in the CNS and neurology markets.
Jazz Pharmaceuticals
JAZZ
Mkt Cap7.16B
Jazz Pharmaceuticals focuses on developing and commercializing innovative pharmaceuticals, including for neurological conditions, directly competing with Supernus.
Acadia Pharmaceuticals
ACAD
Mkt Cap2.75B
ACADIA Pharmaceuticals specializes in the development and commercialization of medicines to treat central nervous system disorders, competing in similar markets as Supernus.
Alkermes
ALKS
Mkt Cap4.68B
Alkermes plc is involved in the development and commercialization of pharmaceuticals for CNS diseases, including schizophrenia and depression, areas where Supernus also operates.
Sage Therapeutics
SAGE
Mkt Cap514.65M
Sage Therapeutics is a biopharmaceutical company focused on developing novel medicines to treat life-altering central nervous system disorders, making it a direct competitor.
Neurocrine Biosciences
NBIX
Mkt Cap12.83B
Neurocrine Biosciences develops and markets pharmaceuticals for neurological and endocrine-related diseases and disorders, competing in the same therapeutic areas as Supernus.
AMGEN
AMGN
Mkt Cap179.38B
Amgen, a biotechnology giant, has a diverse portfolio that includes treatments for neurological disorders, indirectly competing with Supernus in some areas.
Biogen
BIIB
Mkt Cap29.83B
Biogen focuses on neurology, and its portfolio includes treatments for multiple sclerosis and spinal muscular atrophy, competing with Supernus in the neurology space.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie has a broad portfolio that includes CNS treatments, such as Parkinson's and Alzheimer's disease medications, making it a competitor in the neurology market.

Analyst Ratings

36Average Price Target
The highest estimate is €36.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Show more...
CEO
Mr. Jack A. Khattar M.B.A.
Employees
652
Country
US
ISIN
US8684591089
WKN
000A1JX3U

Listings